VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapies for dermatology. The company is headquartered in Bridgewater, New Jersey.
| Revenue (TTM) | 570,000 |
| Gross Profit (TTM) | 570,000 |
| EBITDA | $-29.73M |
| Operating Margin | -4015.00% |
| Return on Equity | -67.00% |
| Return on Assets | -38.30% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $0.83 |
| Price-to-Book | 0.73 |
| Price-to-Sales (TTM) | 36.53 |
| EV/Revenue | 10.04 |
| EV/EBITDA | 1.84 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 54.80% |
| Shares Outstanding | $33.32M |
| Float | $32.53M |
| % Insiders | 4.34% |
| % Institutions | 26.79% |
Volatility is currently contracting